Infliximab, a biologic medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, plays a crucial role in modern medicine. However, medical billing and coding for infliximab can be complex due to its classification under the Healthcare Common Procedure Coding System (HCPCS). Accurate coding ensures proper reimbursement and compliance with healthcare regulations.
This article provides an in-depth exploration of the HCPCS code for infliximab, covering its applications, billing procedures, reimbursement policies, and challenges in medical coding. Whether you’re a healthcare provider, coder, or administrator, this guide will help streamline the billing process while ensuring compliance.
HCPCS Code for Infliximab
2. Understanding Infliximab: Mechanism and Uses
What is Infliximab?
Infliximab (brand name Remicade®, with biosimilars like Inflectra® and Renflexis®) is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). By inhibiting TNF-α, infliximab reduces inflammation in autoimmune conditions.
FDA-Approved Indications
| Condition | FDA Approval Year |
|---|---|
| Crohn’s Disease | 1998 |
| Rheumatoid Arthritis | 1999 |
| Ulcerative Colitis | 2005 |
| Psoriasis | 2006 |
| Ankylosing Spondylitis | 2004 |
Administration and Dosage
Infliximab is administered via intravenous (IV) infusion, typically in a clinical setting. Dosage varies by condition:
-
Crohn’s Disease: 5 mg/kg at weeks 0, 2, and 6 (induction), then every 8 weeks (maintenance).
-
Rheumatoid Arthritis: 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks (often combined with methotrexate).
3. HCPCS Coding System: An Overview
What is HCPCS?
The Healthcare Common Procedure Coding System (HCPCS) is a standardized coding system used for billing Medicare, Medicaid, and private insurers. It consists of two levels:
-
Level I: CPT codes (procedures/services)
-
Level II: HCPCS codes (supplies, drugs, and equipment)
Why is HCPCS Important for Infliximab?
Since infliximab is a biologic drug, it falls under HCPCS Level II for billing purposes. Accurate coding ensures proper reimbursement and minimizes claim denials.
4. HCPCS Code for Infliximab: Detailed Breakdown
Primary HCPCS Codes for Infliximab
| Drug Name | HCPCS Code | Description |
|---|---|---|
| Remicade (Infliximab) | J1745 | Injection, infliximab, 10 mg |
| Inflectra (Infliximab-dyyb) | Q5102 | Injection, infliximab-dyyb, biosimilar, 10 mg |
| Renflexis (Infliximab-abda) | Q5103 | Injection, infliximab-abda, biosimilar, 10 mg |
Billing Units and Dosage Calculation
Since J1745 is billed per 10 mg, providers must calculate the total dosage administered. For example:
-
A patient receives 300 mg of infliximab:
-
300 mg ÷ 10 mg = 30 units
-
Bill 30 units of J1745
-
5. Reimbursement and Billing Considerations
Medicare and Medicaid Reimbursement Policies
-
Medicare Part B: Covers infliximab when administered in a hospital or outpatient setting.
-
Average Sales Price (ASP): Medicare reimburses based on ASP + 6%.
-
Biosimilar Reimbursement: Biosimilars (Q5102, Q5103) may have lower reimbursement rates.
Private Insurance Billing
-
Prior authorization is often required.
-
Documentation must include diagnosis code (ICD-10), medical necessity, and infusion notes.
6. Common Challenges in Coding Infliximab
Frequent Errors Leading to Claim Denials
-
Incorrect Units Billed (e.g., billing per vial instead of per 10 mg).
-
Missing Medical Necessity Documentation.
-
Using Wrong HCPCS Code for Biosimilars.
Solutions to Avoid Denials
-
Verify dosage calculations.
-
Ensure proper documentation (ICD-10 codes: K50.xx for Crohn’s, M05.xx for RA).
7. Regulatory and Compliance Factors
FDA and CMS Guidelines
-
FDA Approval: Only FDA-approved indications are billable.
-
Anti-Kickback Statute: Providers must avoid improper incentives for prescribing infliximab.
Fraud and Abuse Risks
-
Upcoding (billing a higher dose than administered).
-
Unnecessary infusions.
8. Comparative Analysis: Infliximab vs. Other Biologics
| Drug | HCPCS Code | Cost per Dose | Administration |
|---|---|---|---|
| Infliximab | J1745 | $1,200–$1,800 | IV Infusion |
| Adalimumab (Humira) | J0135 | $2,500–$3,000 | Subcutaneous |
| Certolizumab (Cimzia) | J0717 | $1,800–$2,200 | Subcutaneous |
9. Case Studies and Real-World Applications
Case Study 1: Crohn’s Disease Treatment
-
Patient: 35-year-old male with severe Crohn’s.
-
Treatment: Infliximab 5 mg/kg every 8 weeks.
-
Billing: 400 mg dose → 40 units of J1745.
-
Outcome: Successful remission, no claim denials.
10. Future Trends in Infliximab Coding and Usage
-
Increased Biosimilar Adoption (lower costs).
-
Telehealth Infusion Monitoring (new billing codes).
-
Personalized Dosing Adjustments (AI-driven coding).
11. Conclusion
Understanding the HCPCS code for infliximab (J1745, Q5102, Q5103) is essential for accurate billing and reimbursement. Proper documentation, dosage calculation, and compliance with Medicare/Medicaid policies prevent claim denials. As biosimilars gain traction, staying updated on coding changes ensures financial and regulatory success.
12. FAQs
Q1: What is the HCPCS code for Remicade?
A: The HCPCS code for Remicade (infliximab) is J1745 (per 10 mg).
Q2: How do I bill for a 500 mg infliximab infusion?
A: Divide by 10 mg → 50 units of J1745.
Q3: Are biosimilars billed differently?
A: Yes, Inflectra (Q5102) and Renflexis (Q5103) have separate codes.
Q4: Does Medicare cover infliximab for psoriasis?
A: Only if medically necessary and FDA-approved.
13. Additional Resources
-
CMS HCPCS Code Lookup: https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets
-
FDA Infliximab Guidelines: https://www.fda.gov/drugs
-
American Medical Association (AMA) CPT Codes: https://www.ama-assn.org
